Skip to main content
Medicine LibreTexts

7.2: Sickle Cell (Hemoglobin SS) Disease

  • Page ID
    38803
  • \( \newcommand{\vecs}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \)

    \( \newcommand{\vecd}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash {#1}}} \)

    \( \newcommand{\id}{\mathrm{id}}\) \( \newcommand{\Span}{\mathrm{span}}\)

    ( \newcommand{\kernel}{\mathrm{null}\,}\) \( \newcommand{\range}{\mathrm{range}\,}\)

    \( \newcommand{\RealPart}{\mathrm{Re}}\) \( \newcommand{\ImaginaryPart}{\mathrm{Im}}\)

    \( \newcommand{\Argument}{\mathrm{Arg}}\) \( \newcommand{\norm}[1]{\| #1 \|}\)

    \( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\)

    \( \newcommand{\Span}{\mathrm{span}}\)

    \( \newcommand{\id}{\mathrm{id}}\)

    \( \newcommand{\Span}{\mathrm{span}}\)

    \( \newcommand{\kernel}{\mathrm{null}\,}\)

    \( \newcommand{\range}{\mathrm{range}\,}\)

    \( \newcommand{\RealPart}{\mathrm{Re}}\)

    \( \newcommand{\ImaginaryPart}{\mathrm{Im}}\)

    \( \newcommand{\Argument}{\mathrm{Arg}}\)

    \( \newcommand{\norm}[1]{\| #1 \|}\)

    \( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\)

    \( \newcommand{\Span}{\mathrm{span}}\) \( \newcommand{\AA}{\unicode[.8,0]{x212B}}\)

    \( \newcommand{\vectorA}[1]{\vec{#1}}      % arrow\)

    \( \newcommand{\vectorAt}[1]{\vec{\text{#1}}}      % arrow\)

    \( \newcommand{\vectorB}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \)

    \( \newcommand{\vectorC}[1]{\textbf{#1}} \)

    \( \newcommand{\vectorD}[1]{\overrightarrow{#1}} \)

    \( \newcommand{\vectorDt}[1]{\overrightarrow{\text{#1}}} \)

    \( \newcommand{\vectE}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash{\mathbf {#1}}}} \)

    \( \newcommand{\vecs}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \)

    \( \newcommand{\vecd}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash {#1}}} \)

    Cause(s):

    β globin chain amino acid substitution in the 6th position from glutamic acid (Glu) to valine (Val). In the homozygous form of the disease, both β globin genes are affected.1

    Inheritance:

    Autosomal dominant2

    Demographics:3

    Tropical Africa

    Mediterranean Areas

    Sickle cell disease is common in areas where malaria is prominent and it is suggested that the disease acts as a protective factor for malaria. This protection is only seen in heterozygotes, as homozygotes often lose splenic function, which is essential for combating the parasite.

    Cellular Features:1-4

    See sickle cell (drepanocytes) under RBC morphology for more information about cell formation.

    The formation of sickle cells becomes irreversible over time leading to the formation of rigid and “sticky” sickle cell aggregates resulting in many complications.

    Complications:1-4

    Chronic hemolytic anemia

    Vaso-occlusion (can lead to ischemic tissue injury, splenic sequestration of RBCs, autosplenectomy)

    Prone to infections

    Nephropathies

    Stroke

    Laboratory Features of Sickle Cell Disease:2-4

    CBC:

    RBC: Decreased

    WBC: Increased

    PLT: Increased

    Hb: Decreased

    RETIC: Increased

    RDW: Increased

    PBS:

    Sickle cells

    Normochromic, normocytic RBCs

    Target cells

    Polychromasia

    nRBCs

    Howell-Jolly bodies

    Pappenheimer bodies

    Basophilic Stippling

    BM:

    Erythroid Hyperplasia

    Iron stores: often increased

    Hemoglobin Electrophoresis:

    Hb S: 80-95%

    Hb A: None

    Hb A2: 2-%

    Hb F: 5-20%

    Other Tests:

    Solubility Screen: Positive

    Metasulfite Sickling Test: Positive

    HPLC

    Hemoglobin Electrophoresis

     

    References:

    1. Chonat S, Quinn CT. Current standards of care and long term outcomes for thalassemia and sickle cell disease. Adv Exp Med Biol [Internet]. 2017 [cited 2018 Jun 5];1013:59–87. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720159/

    1. Randolph TR. Hemoglobinopathies (structural defects in hemoglobin). In: Rodak’s hematology clinical applications and principles. 5th ed. St. Louis, Missouri: Saunders; 2015. p. 426-453.

    3. Laudicina RJ. Hemoglobinopathies: qualitative defects. In: Clinical laboratory hematology. 3rd ed. New Jersey: Pearson; 2015. p.231–50.

    4. Harmening DM, Yang D, Zeringer H. Hemolytic anemias: extracorpuscular defects. 5th ed. Philadelphia: F.A. Davis Company; 2009. p. 250-79).


    This page titled 7.2: Sickle Cell (Hemoglobin SS) Disease is shared under a CC BY-NC 4.0 license and was authored, remixed, and/or curated by Valentin Villatoro and Michelle To (Open Education Alberta) via source content that was edited to the style and standards of the LibreTexts platform; a detailed edit history is available upon request.